1Cairo M S, Bishop M. Tumor lysis syndrome: new therapeutic strategies and classification[J]. Br J Haematol,2001,127(1):3- 11.
2Otrock Z K, Hatoum H A, Salem Z M. et al. Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma [J]. Intern Emerg Med.2008.3(2):161-163.
3Fleming D R. Doukas M A. Acute lumor lysis syndrome in hematologic malignancies [J]. Leuk Lymphoma. 1992,8(4-5): 315-318.
4Cohen I. F, Balow J E. Magrath I T, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt's lymphoma[J]. Am J Med,1980,68(4):486-491.
5Hande K R, Garrow G C. Acute lumor lysis syndrome in patients with high grade non Hodgkin's lymphoma[J]. Am J Med, 1993, 94(2) : 133-139.
6Locatelli F, Rossi F. Incidence and pathogenesis of tumor lysis syndrome[J]. Contrib Nephrol,2005,147:61-68.
8McLaughlin P, Grillo-Lopez A J, Link B K, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four dose treatment program[J]. J Clin Oncol,1998.16(8):2825-2833.
2Agha-Razii M, Amyot S L, Pichette V,et al. Continiuos veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicating by acute renal failure and severe hyperuricemia[J]. Clin Nephrol, 2000,1:59-63.
3Flombam C D. Metabolic emergencies in the cancer patient [J]. Semim Oncol,2000, 3:322-344.
4Vaishan E, Braester A, Mosezon O, et al. Spontaneous tumor lysis syndrome in tumors: really a rare condition[J]. J Am Med Sci, 2003, 325:38-40.
6Sklarin N, Markham M. Spontaneous tumor lysis syndrome [J]. Am J Clin Oncol, 1995, 18: 71-73.
7Kalemkerian G P, Darwish B, Vartasian M L. Tumor lysis syndrome in small carcinoma and other solid tumors [J].Am J Med, 1997, 103:363-367.
8Feld J, Mehta H, Burkes R L. Acute Spontaneous tumor lysis syndrome in adenocarcinoma of the lung a case report[J]. Am J Clin Oncol, 2000, 23:491-493.
9Drakoa P, Bar-Ziv J, Cotame R. Tumor lysis syndrome in non-hemalologic malignancies report a case and review of the literature [J]. Am J Clin Oncol,1994, 17:502-505.
10Sallan S. Management of acute tumor lysis syndrome[J]. Semin Oncol, 2001,28 (suppl 5):9-12.
4PLOSKER G L,FIGGITT D P.Rituximab:a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia[J].Drugs,2003,63(8):803-843.
5Sonet A,Bosly A.Rituximab and chemotherapy in diffuse large B-cell lymphoma[J].Expert Rev Anticancer The,2009,9(6):719-726.
6Aksoy S,Dizdar O,Hayran M,et al.Infectious complications of rituximab in patients with lymphoma during maintenance therapy:a systematic review and meta-analysis[J].Leuk Lymphoma,2009,50(3):357-365.
8Cairo MS.Coiffier B.Reiter Av e; al. Recommendations for the e-valuation of risk and prophylaxis of tumor lysis syn?drornet.TL'S) inadults and children with malignant disea?ses: an expert TLS panel consensus[J]. BrJ Haematol , 2010.149(2) :578-586.
9Abou Mourad Yv Taller Av Shamseddine A. Acute tumorl?ysis syndrome in larse B-cell non- Hodgkin lymphoma in?duced by steroids and anti-CD20[J]. HematolJ. 2003. 4 (3): 222-224.
10. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non- Hodgkins lymphoma[J]. AmJ Med, 1993,94(2): 133-139.
